BNP Paribas Financial Markets
PRVL

BNP Paribas Financial Markets’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

BNP Paribas Financial Markets’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,790
Closed -$64.4K – 4240
2020
Q4 		$64.4K Sell
2,790
-567
-17% -$7.19K ﹤0.01% 3437
2020
Q3 		$34.2K Buy
3,357
+2,789
+491% +$37.4K ﹤0.01% 3636
2020
Q2 		$8.46K Sell
568
-3,574
-86% -$55.1K ﹤0.01% 3778
2020
Q1 		$50.5K Buy
4,142
+3,279
+380% +$52.2K ﹤0.01% 3536
2019
Q4 		$13.7K Sell
863
-75
-8% -$957 ﹤0.01% 4089
2019
Q3 		$11.5K Buy
+938
New +$10.6K ﹤0.01% 4125

BNP Paribas Financial Markets's PRVL Position: Q1 2021 in Review

BNP Paribas Financial Markets sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 2,790 shares — an estimated $64.4K sold.

BNP Paribas Financial Markets first reported a position in PRVL in Q3 2019 and held it in 6 quarters. The position peaked at $64.4K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • BNP Paribas Financial Markets reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 2,790 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $64.4K.
  • BNP Paribas Financial Markets first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2019 and held it in 6 quarters.
  • BNP Paribas Financial Markets's Prevail Therapeutics Inc. Common Stock position peaked at $64.4K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2021, filed 7 May 2021.